Physician profile
Syed Imam
NPI 1366428286
$2,163.52
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $492 · 2020: $115 · 2021: $432 · 2022: $381 · 2023: $598 · 2024: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $633 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $632.54 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $301.74 | 2019-2024 | Austedo Xr, Austedo, Uzedy |
| Neurocrine Biosciences, INC. | $275.45 | 2019-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $272.13 | 2019-2024 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $258.70 | 2019-2024 | Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $195.72 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $194.02 | 2019-2022 | |
| Abbvie INC. | $191.68 | 2021-2024 | |
| Indivior INC. | $70.09 | 2021-2024 | Perseris |
| Supernus Pharmaceuticals, INC. | $69.24 | 2021-2023 | Qelbree |
| Acadia Pharmaceuticals INC | $57.49 | 2022-2024 | Nuplazid |
| Sunovion Pharmaceuticals INC. | $54.04 | 2019 | |
| Avanir Pharmaceuticals, INC. | $44.37 | 2022 | |
| Noven Therapeutics, LLC | $39.31 | 2022-2024 | Secuado, Xelstrym |
| Vanda Pharmaceuticals INC. | $38.91 | 2019-2021 | |
| Lundbeck LLC | $25.34 | 2019-2023 | Rexulti |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $23.16 | 2019 | |
| Axsome Therapeutics, INC. | $14.05 | 2023 | Auvelity |
| Shire North American Group INC | $13.15 | 2019 | |
| Allergan, INC. | $13.01 | 2019 | |
| Jazz Pharmaceuticals INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Imam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.